Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

Antoine Italiano,Loic Verlingue,Hans Prenen,Eva Guerra,Diego Tosi,Ruth Perets,Iwona Lugowska,V. Moiseenko,Mahmut Gumus,Cagatay Arslan,Colin R. Lindsay,Muriel Richard,David Dejardin,Christophe Boetsch,Anton Kraxner,Stefan Evers,Taner Vardar,Nino Keshelava,Volker Teichgräber,Rafal Dziadziuszko

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

2021

5510Background: Simlukafusp alfa (SIM; FAP-IL2v) comprises an interleukin-2 variant (IL-2v) moiety and an antibody against fibroblast activation protein-α (FAP). The binding of SIM to FAP, expresse...

Keywords:

Cancer research
Metastatic cervical cancer
Fibroblast activation protein, alpha
in patient
Medicine
Antibody
Atezolizumab
Interleukin 2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations